HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.106.036673v1 48/6/902    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ho, C.-l. Articles by Cheng, T. K.C. Search for Related Content PubMed PubMed Citation Articles by Ho, C.-l. Articles by Cheng, T. K.C.

Dual-Tracer PET/CT Imaging in Evaluation of Metastatic Hepatocellular Carcinoma

Department of Nuclear Medicine and PET, Hong Kong Sanatorium and Hospital, Hong Kong, China

Correspondence: For correspondence or reprints contact: Chi-lai Ho, MD, Department of Nuclear Medicine and PET, Hong Kong Sanatorium and Hospital, 2 Village Rd., Happy Valley, Hong Kong, China. E-mail: garrettho{at}hksh.com

We have reported previously that ¹¹C-acetate (¹¹C-ACT) PET was complementary to ¹⁸F-FDG PET in the evaluation of primary hepatocellular carcinoma (HCC) in relation to the degree of tumor cellular differentiation. In this retrospective study, our goals were to further explore the complementary role of ¹¹C-ACT and ¹⁸F-FDG PET in the detection of metastatic HCC disease, to evaluate the tracer characteristics of individual organ metastasis, to identify the risk factors of metastasis, and to evaluate how these results could affect patient management. Methods: One hundred twenty-one patients were selected for this study. All patients had undergone a "dual-tracer" PET/CT same-day protocol with ¹¹C-ACT PET/CT followed by ¹⁸F-FDG PET/CT. Sets of criteria were chosen to define "metastasis" and "no metastasis" on a patient basis. The patients considered as true-positive (n = 97) were then divided into 4 groups on the basis of their primary HCC tracer avidity: ¹⁸F-FDG-avid group, ¹¹C-ACT-avid group, ¹⁸F-FDG- and ¹¹C-ACT-avid group, and a posttreatment group with metastasis but no baseline dual-tracer PET characterization of the primary tumor and no hepatic recurrence. Results: On a patient basis, dual-tracer PET/CT had a sensitivity of 98%, a specificity of 86%, a positive predictive value of 97%, a negative predictive value of 90%, and an accuracy of 96% in the detection of HCC metastasis. On a lesion basis, 273 metastatic HCC lesions considered as true-positive were detected and categorized according to the organ or site of metastasis: lymph node (abdominal and thoracic, 49%), lung (32%), bone (8%), and others (10%). The lesion-based and patient-based detection sensitivities were 60% and 64%, respectively, by ¹¹C-ACT and 77% and 79%, respectively, by ¹⁸F-FDG, and they were complementary. In analyzing lesion tracer avidity, there was a positive statistical correlation between primary HCC avidity with the general tendency of metastasis. Clinically significant changes in management were found in patients with true-positive metastasis, of whom 19% were affected by ¹¹C-ACT PET alone. Dual-tracer PET/CT was more effective than single-tracer PET/CT in identifying candidates for curative therapy (negative predictive value of dual-tracer, ¹⁸F-FDG, and ¹¹C-ACT PET/CT: 90%, 49%, and 37%, respectively). Conclusion: This study confirmed that ¹⁸F-FDG PET/CT is useful in the evaluation of HCC metastasis, although its role in the diagnosis of primary HCC is more limited. Dual-tracer PET/CT had an incremental value and complementary advantage when compared with single-tracer imaging in the evaluation of HCC metastasis.

Key Words: ¹¹C-acetate • ¹⁸F-FDG • PET/CT • hepatocellular carcinoma • metastasis

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  

This article has been cited by other articles:

				D. Y. Lee and K. C. P. Li Systems Diagnostics: The Systems Approach to Molecular Imaging Am. J. Roentgenol., August 1, 2009; 193(2): 287 - 294. [Abstract] [Full Text] [PDF]

				J.-W. Park, J. H. Kim, S. K. Kim, K. W. Kang, K. W. Park, J.-I. Choi, W. J. Lee, C.-M. Kim, and B. H. Nam A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma J. Nucl. Med., December 1, 2008; 49(12): 1912 - 1921. [Abstract] [Full Text] [PDF]

				Y. Yamamoto, Y. Nishiyama, R. Kameyama, K. Okano, H. Kashiwagi, A. Deguchi, M. Kaji, and M. Ohkawa Detection of Hepatocellular Carcinoma Using 11C-Choline PET: Comparison with 18F-FDG PET J. Nucl. Med., August 1, 2008; 49(8): 1245 - 1248. [Abstract] [Full Text] [PDF]

				J. Tian, X. Yang, L. Yu, P. Chen, J. Xin, L. Ma, H. Feng, Y. Tan, Z. Zhao, and W. Wu A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3'-Deoxy-3'-18F-Fluorothymidine and 18F-FDG J. Nucl. Med., February 1, 2008; 49(2): 186 - 194. [Abstract] [Full Text] [PDF]